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Abstract
Background: Myocardial dysfunction needing inotropic support is a typical complication
after on-pump cardiac surgery. In this study, we evaluate the effect of milrinone on patients
with ventricular dysfunction undergoing coronary artery bypass graft (CABG).
Methods: Seventy patients with impaired left ventricular function [left ventricular ejection
fraction (LVEF) < 35%] undergoing on-pump CABG were enrolled. Patients were randomized
to receive either an intraoperative bolus of milrinone (50 μg/kg) or saline as placebo followed by
a 24-hour infusion of each agent (0.5 μg/kg/min). Hemodynamic parameters and transthoracic
echocardiographic measurement of systolic and diastolic functions were the variables evaluated.
Results: Serum levels of creatine phosphokinase (CPK), the MB isoenzyme of creatine kinase
(CK-MB), occurrence of myocardial ischemia or infarction, and mean duration of using
inotropic agents were significantly lower in the milrinone group (p < 0.05). There were no
significant differences between the two groups regarding the development of ventricular
arrhythmia, duration of cardiopulmonary bypass, intra-aortic balloon pump and inotropic
support requirement, duration of mechanical ventilation, duration of intensive care unit stay
and mortality rate. Although mean pre-operative LVEF was significantly lower in the milrinone
group, there was no significant difference between post-operative LVEFs.
Conclusions: We suggest that perioperative administration of milrinone in patients undergo-
ing on-pump CABG, especially those with low LVEF, is beneficial. (Cardiol J 2010; 17, 1: 73–78)
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Introduction
Myocardial dysfunction requiring inotropic
support is a typical complication following on-pump
cardiac surgery [1]. Low-output syndrome (LOS) is
a major complication in approximately 30% of pa-
tients with reduced ventricular function undergo-
ing coronary artery bypass graft (CABG) with car-
diopulmonary bypass (CPB) [2]. This condition
leads to delayed recovery, organ failure, increased
duration of intensive care unit (ICU) stay, and high-
er hospital costs [3]. Furthermore, in patients with
weak ventricular function, the LOS adds to the risk
of early post-operative mortality [2].
Reversal of the LOS is needed to improve
myocardial contractility and tolerate cardiac load-
ing conditions which are achieved by instituting
appropriate inotropic drugs and fluid management
plans [4].
Myocardial b1-receptor desensitization occurs
chronically in patients with congestive heart failure
[5, 6] and acutely following CPB [7], therefore limi-
ting the efficacy of b-agonists for post-CABG car-
diac failure. Phosphodiesterase-III inhibitors, in-
cluding milrinone and amrinone, provide an alter-
native means of inotropic support via non
b1-adrenergic pathways and vasodilatation [8, 9].
These agents also improve hemodynamic parame-
ters and increase blood flow of the grafted internal
mammary arteries as well as middle cerebral arte-
ries during CABG [2].
Previous studies have revealed that both mil-
rinone and amrinone improve ventricular function
and hemodynamic status after CPB in patients who
have been treated with catecholamines and nitro-
glycerin for a long time [10–12].
There are limited studies evaluating the effects
of milrinone on cardiac function in patients with
LOS who undergoing CABG. The present study was
designed to test the hypothesis that milrinone can
reduce the risk of developing myocardial ischemia
and infarction after CABG in patients with pre-ex-
isting myocardial dysfunction.
Methods
Patients
This study was reviewed and approved by the
local ethical committee of Tehran University of
Medical Sciences. All participants gave  written in-
formed consent pre-operatively. Seventy consecu-
tive patients with left ventricular ejection fraction
(LVEF) lower than 35% [13, 14] who were selected
for elective isolated CABG, enrolled in a random-
ized, double-blind, placebo controlled trial at Sha-
riati Hospital. Patients who underwent emergency
CABG, those with myocardial infarction (MI) or
ventricular arrhythmias within 72 hours before the
operation, and those requiring inotropic support
prior to the surgery were excluded. Concomitant
valvular heart disease and left bundle branch block
were other exclusion criteria.
Seventy eligible patients were randomly as-
signed to receive milrinone (n = 35) or a placebo
(n = 35) intravenously within 24 hours after CABG.
Milrinone or a saline placebo was administered as
a bolus dose (50 μg/kg) immediately after CABG
and continued as an infusion (0.5 μg/kg/min) for
24 hours later.
A need for inotropic support was defined as
observation of diminished cardiac contractility by
using transthoracic echocardiography and inspec-
tion of the right ventricle during and after weaning
[15]. Inotropic support was provided by using a sec-
ond inotrope without vasodilator activity (dopam-
ine). Second inotropic agents were administered
after giving milrinone if needed.
All operations were done by the same cardiac
surgery team. Utilizing visual inspection, LVEFs
were measured 24 hours before and 24 hours after
each operation by a single expert cardiologist who
was blind to the study.
Surgical technique
In both groups, a standard CPB technique was
used. Median sternotomy and harvesting of the in-
ternal mammary artery as pedicled fashion were
followed by full exposure of the coronary artery
branches to be revascularized. Then, the left inter-
nal mammary artery was used as the main graft on
the left anterior descending artery and the saphen-
ous vein was utilized as a conduit for other coro-
nary arteries.
All patients underwent on-pump CABG with
moderate hypothermia and simultaneous retro- and
ante-grade blood cardioplegia.
Following aortic clamp removal, milrinone or
saline (placebo) administered as an intravenous
(IV) bolus dose of 50 μg/kg followed by infusion of
0.5 μg/kg/min during the next 24 hours.
Measurement of variables
Creatine phosphokinase (CPK) and creatine
kinase MB (CK-MB) were measured immediately
after the surgery and four and 24 hours later. Re-
quired data including demographics , pre- and post-
-operation LVEF, CPK and CK-MB levels, CK-MB/
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/CPK ratio, CPB time, duration of inotropic support,
length of ICU stay as well as appearance of ventricu-
lar arrhythmia, and the need for an intra-aortic bal-
loon pump (IABP) were recorded for each patient.
Evidence of myocardial ischemia and develop-
ment of MI were also recorded. New ST depres-
sion (at least 0.1 mV) or new ST elevation (at least
0.2 mV) on electrocardiography were considered as
evidence of myocardial ischemia. Development of
MI was defined as rising in CPK, CK-MB or CK-
-MB/CPK ratio more than 6% concomitant with
electrocardiography changes (appearance of new Q
wave or conductive abnormality) or echocardio-
graphic evidence of ischemia (new wall motion ab-
normality) were also recorded.
Statistical analysis
The primary endpoint of this study was deve-
lopment of myocardial ischemia and/or MI. Other
endpoints were cardiac enzyme levels and duration
of inotropic support. Sample size and power were
estimated by determining the number of patients
required to show the significant difference between
risk ratio of the ischemic evidence development
by eight hours after CABG. It was determined that
33 patients in each group (66 in total) would be re-
quired to show a statistically significant difference
between the two groups using an alpha of 0.05 and
power of 80%. We enrolled two extra patients in
each group in case a patient dropped out of the
study. SPSS software (SPSS Inc., Chicago IL. ver-
sion 11.5) was used for statistical analysis. Indepen-
dent samples t-test, c2 and Fischer’s exact test were
used for statistical analysis. A p value < 0.05 was
considered statistically significant.
Results
Data was collected for 70 consecutive patients
meeting the inclusion criteria, with 35 in each study
group. A comparison of baseline demographic infor-
mation, as well as pre-operative and post-operative
variables by treatment group, is presented in Table 1.
Mean age of the patients was 57.6 ± 9.1 (mean ±
± standard deviation) and ranged from 33 to
75 years. Of the 70 patients, 53  were male. There
were no significant differences between the two
study groups regarding age and sex distributions.
The number of grafts which were used ranged
from one to six. Although the mean duration of CPB
was longer in the control group (96.5 min for con-
trol and 92.9 for milrinone), it was not statistically
significant (p > 0.05).
The values of CPK (Fig. 1) and CK-MB (Fig. 2)
measured immediately after operation, four hours,
and 24 hours later, were significantly lower in the
milrinone group, while the CK-MB/CPK ratio was
comparable in both groups (Fig. 3). Evidence of
myocardial ischemia on electrocardiography after 24
hours was found in 16 patients of the placebo group
and in four patients of the milrinone group (p =
= 0.003, odds ratio: 6.53 with 95% confidence inter-
val: 1.90–22.45). Evidence of MI after 24 hours was
found in eight patients, all belonging to the placebo
group (p = 0.005). Ventricular arrhythmia occurred
in five and ten patients in the milrinone and control
groups respectively, which was not statistically sig-
nificant (p = 0.244). In addition, there was no sig-
nificant difference between the two groups regard-
ing IABP requirement (one in the milrinone and four
in the control group, p = 0.35). Inotropic support
Table 1. Comparison of baseline characteristics of patients between two groups.
Milrinone (n = 35) Control (n = 35) P
Age 56.9 ± 9.7 58.2 ± 8.4 0.57
Sex (male/female) 25/10 28/7 0.58
Diabetes (%) 25.7 20 0.77
Hypertension (%) 54.3 60 0.80
Prior myocardial infarction (%) 42.9 51.4 0.63
Three vessels CAD (%) 40 45.7 0.80
≥ 3 grafts (%) 63 49 0.22
Pre-operative LVEF (%) 31.8 ± 3.2 34.5 ± 1.4 0.001*
Post-operative LVEF (%) 34.7 ± 4.5 33.1 ± 3.2 0.098
Data presented as mean ± standard deviation; LVEF — left ventricular ejection fraction; CAD — coronary artery disease; *significant difference (inde-
pendent samples t-test)
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Figure 2. Creatine kinase MB (CK-MB) concentrations
among study groups measured immediately after sur-
gery (0 h), at four hours (4 h), and at 24 hours (24 h)
following the procedure; *indicates the significant dif-
ference between milrinone and control groups.
Figure 1. Creatine phosphokinase (CPK) concentrations
among study groups measured immediately after sur-
gery (0 h), at four hours (4 h), and at 24 hours (24 h)
following the procedure; *indicates the significant dif-
ference between milrinone and control groups.
was used in 33 patients in the milrinone group and
32 patients in the control group (p = 0.99), while
duration of inotropic support was longer in the con-
trol group (p = 0.007). The mean pre-operative
LVEF was lower in the milrinone group (p = 0.001),
while the difference between post-operative LVEFs
was not significant (p = 0.098; Table 2). The mean
ICU stay was 2.4 (range from one to four) days and
2.1 (range from one to three) days in the control
and milrinone groups respectively (p > 0.05). No
resternotomy, stroke or renal failure occurred. Post-
operative death occurred in two patients (both in the
control group, due to cardiogenic shock) while no
death occurred among patients treated with milrino-
ne. However, the difference was not statistically sig-
nificant (p > 0.05).
Discussion
Our results revealed that administration of
bolus doses of milrinone, followed by continuous
maintenance infusion for about 24 hours post-ope-
ratively, will reduce the serum level of CPK, CK-
-MB and evidence of myocardial ischemia and inf-
arction in patients with impaired left ventricular
function undergoing CABG. We used a bolus mil-
rinone dose of 50 μg/kg with an infusion at the rate
of 0.5 μg/kg/min because it had previously been
found that it maintains plasma concentrations at the
threshold of therapeutic effects or above [16].
Myocardial ischemia and infarction are major
complications immediately after coronary artery
bypass grafting. They may be due to incomplete
surgical revascularization, perioperative anesthet-
ic management or vasospasm of arterial grafts, e.g.
the internal mammary artery [17]. The efficacy and
safety of milrinone for treatment of LOS are well
known [18, 19]. Furthermore, it has been shown
that milrinone lessens myocardial ischemia and cell
damage after elective CABG [17]. We also observed
high rates of MI and myocardial ischemia in the pla-
cebo group (eight and 16 cases respectively) which
shows that milrinone protects against serious my-
ocardial ischemia. There are also several experi-
mental studies that suggest protective effects of
phosphodiesterase III inhibitors against myocardial
ischemia on both right and left ventricles [20, 21].
Sanada et al. [21] suggested that pretreatment with
phosphodiesterase III inhibitors such as milrinone
has cardioprotective effects in canine hearts. These
cardioprotective effects are exerted via cAMP-,
protein kinase A-, and p38 mitogen-activated pro-
tein kinase-dependent but protein kinase C-inde-
pendent mechanisms in canine hearts.
Figure 3. Creatine kinase MB (CK-MB) to creatine phospho-
kinase (CPK) — CK-MB/CPK ratios among study groups
measured immediately after surgery (0 h), at four hours
(4 h), and at 24 hours (24 h) following the procedure.
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used for end organ perfusions are other limitations.
Also we had no data on Swan-Ganz measurements
of cardiac function.
Conclusions
The present study demonstrates that admin-
istration of milrinone in patients undergoing on-
pump CABG, especially those with low LVEF, may
decrease MI rate and duration of inotropic support.
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